Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
about
Direct anti-HCV agentsInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceTherapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisInvestigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionMechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Beclabuvir for the treatment of hepatitis C.Synergistic Activity of Combined NS5A Inhibitors.Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO), All-Oral, Fixed-Dose Combination for Patients With Chronic HCV Genotype 1.Allosteric mechanism of cyclopropylindolobenzazepine inhibitors for HCV NS5B RdRp via dynamic correlation network analysis.Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.Current and future targets of antiviral therapy in the hepatitis C virus life cycle
P2860
Q26767329-968328BA-ADE2-4731-983B-83B5BDC9194BQ26783056-3848FAC8-62F6-4B4F-A50D-F4E46348A053Q28070260-30A962C0-C701-4FEF-86ED-FCC5FED905A6Q31051529-D0F755A5-D913-4001-9AB4-F497CD392133Q33797808-07E00787-82C8-4501-A66C-BCE6054ABA98Q34580349-8D016918-BBD0-43D9-B4D9-7242383D0240Q34597529-3B814C9D-4412-4D6D-9329-C7BA9B5A6039Q37615174-531454F1-EEEA-4334-99DE-6510268814E1Q38515906-A47102D8-ED31-471B-BC6A-8EB1C4598675Q38533619-E64DC544-E220-45EF-8581-F58C17B67E84Q38544196-BFB17942-0E12-4E49-B57E-E55BC54132FEQ38741143-7746523A-7963-49C0-80B4-A507CA9321ABQ38859479-441322CD-1F47-4147-A06B-AC3CA07DD2C6Q40536980-9C6BC845-A896-40BD-91EB-1B791F44C97BQ40587241-93AC188D-DF85-4303-955C-37C4A47130A1Q41585354-9FC9CD58-4E13-4B3F-A2CA-8E8998D52577Q41605573-77CB20C5-6264-4B86-B846-F17EBC145AA4Q47278098-2C9077C2-83B4-4C40-9A05-426A20402311Q57071775-1B0B2576-0442-4178-AE17-1C0205F56400
P2860
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@ast
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@en
type
label
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@ast
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@en
prefLabel
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@ast
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@en
P2093
P2860
P356
P1476
Preclinical characterization o ...... titis C Virus NS5B polymerase.
@en
P2093
Jay O Knipe
John A Bender
John F Kadow
Julie A Lemm
Karen L Rigat
Kathleen W Mosure
Kenneth S Santone
Lenore A Pelosi
Mengping Liu
P2860
P304
P356
10.1128/AAC.02495-13
P407
P577
2014-04-14T00:00:00Z